Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab. The ...

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients ORLANDO, ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Patients were randomly ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

How Will I Get Imbruvica? Imbruvica is taken as a tablet, capsule, or liquid suspension that you swallow. The typical dosage is 420 milligrams of Imbruvica once a day. You should take your dose around ...

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more ...